*Not available for sale in all countries. Please check with your local distributor for availability in your country.
Iridex provides office-based laser solutions for your retina practice. With the patented Fovea-friendly™ MicroPulse® laser technology there is a treatment option for the most common retinal diseases.
Iridex offers high quality laser systems, EndoProbe® handpieces, and a portfolio of vitreoretinal consumables for precision surgery in the hospital and ASC.
Iridex laser systems provide traditional, MicroPulse, and transscleral laser solutions for the management of glaucoma.
Iridex products offer the versatility of traditional, MicroPulse, and transscleral laser options for the treatment of both glaucoma and retinal diseases.
July 29, 2025: Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema
March 19, 2025: Iridex Announces Strategic Investment in the Company
December 18, 2024: Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management
October 03, 2024: Iridex Appoints Patrick Mercer as Chief Executive Officer
May 31, 2024: Iridex to Showcase Advancements in Glaucoma Laser Solutions at the 16th European Glaucoma Society (EGS) Congress in Dublin, June 1-4, 2024
February 6, 2024: Iridex Corporation Receives European Patent on MicroPulse Technology
January 25, 2024: Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
January 12, 2024: Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma